Iovance Biotherapeutics, Inc.
IOVA
$3.78
-$0.10-2.58%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 285.61M | 263.50M | 250.43M | 241.53M | 212.68M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 285.61M | 263.50M | 250.43M | 241.53M | 212.68M |
| Cost of Revenue | 180.75M | 180.97M | 175.65M | 168.69M | 143.39M |
| Gross Profit | 104.86M | 82.54M | 74.78M | 72.84M | 69.29M |
| SG&A Expenses | 147.60M | 152.45M | 158.38M | 163.16M | 165.03M |
| Depreciation & Amortization | 27.06M | 26.59M | 26.23M | 26.95M | 26.95M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 643.64M | 661.72M | 661.75M | 652.16M | 611.46M |
| Operating Income | -358.04M | -398.21M | -411.33M | -410.64M | -398.78M |
| Income Before Tax | -354.76M | -393.05M | -398.33M | -389.73M | -378.62M |
| Income Tax Expenses | -898.00K | -2.07M | -697.00K | 188.00K | -3.26M |
| Earnings from Continuing Operations | -353.86 | -390.98 | -397.63 | -389.92 | -375.36 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -353.86M | -390.98M | -397.63M | -389.92M | -375.36M |
| EBIT | -358.04M | -398.21M | -411.33M | -410.64M | -398.78M |
| EBITDA | -321.75M | -362.40M | -371.45M | -371.96M | -360.69M |
| EPS Basic | -0.95 | -1.12 | -1.20 | -1.23 | -1.23 |
| Normalized Basic EPS | -0.59 | -0.70 | -0.76 | -0.79 | -0.80 |
| EPS Diluted | -0.95 | -1.12 | -1.20 | -1.23 | -1.23 |
| Normalized Diluted EPS | -0.59 | -0.70 | -0.76 | -0.79 | -0.80 |
| Average Basic Shares Outstanding | 1.52B | 1.43B | 1.33B | 1.27B | 1.22B |
| Average Diluted Shares Outstanding | 1.52B | 1.43B | 1.33B | 1.27B | 1.22B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |